TP53 and acute myeloid leukemia: The present study included several patients with high-risk leukemia, i.e., AML relapse (seven patients), secondary AML (ten patients), complex karyotype (five patients) and/or tumor protein p53 (TP53) mutations (two patients) (Table 1).